Skip to main content

13.05.2016 | Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor) | Ausgabe 2/2016

Current Breast Cancer Reports 2/2016

Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?

Current Breast Cancer Reports > Ausgabe 2/2016
Richard Gilmore, David M. Euhus
Wichtige Hinweise
This article is part of the Topical Collection on Local-Regional Evaluation and Therapy


Through most of recorded medical history, there has been debate about how much healthy tissue should be removed in order to effectively treat breast cancer. The prevailing opinion at the start of the twentieth century was “a lot.” The trend has been reversed in recent decades as advances in systemic treatments and radiation therapy have pushed local recurrence rates down even as breast surgery has become markedly less destructive. There is still debate, however, over the nipple-areolar complex in patients requiring mastectomy. A wealth of data has now accumulated demonstrating that occult nipple involvement with cancer is rare, and usually identifiable in appropriately obtained tissue samples; that leaving the nipple behind does not need to leave a lot of breast tissue behind; that the nipple is not a favored site of recurrence; and that local recurrence rates are quite low in selected breast cancer patients treated with nipple-sparing mastectomy. There has been concern, however, that BRCA gene mutation carriers may be at greater than average risk for new primary breast cancers if the nipple is preserved. Available case series are small and follow-up is short, but thus far, there is no signal to suggest that this is the case. Thorough, oncologically sound nipple-sparing mastectomy appears safe in BRCA gene mutation carriers.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

Current Breast Cancer Reports 2/2016 Zur Ausgabe

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Margins in Breast-Conserving Surgery for Early Breast Cancer: How Much is Good Enough?

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Role of Breast MRI in Patients with Newly Diagnosed Breast Cancer

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Regional Nodal Radiotherapy in Early-Stage Breast Cancer: Where Are We in 2016?

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.